Physician profile
Luis Wulff
NPI 1144678392
$3,606.41
in general payments reported to CMS, 2019-2025
27 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.68 · 2023: $474 · 2024: $1,559 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Travel and Lodging: $238 · Consulting Fee: $200 · Education: $97.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.55 |
| Travel and Lodging | $237.86 |
| Consulting Fee | $200.00 |
| Education | $97.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $823.84 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Intuitive Surgical, INC. | $444.56 | 2023-2025 | Da Vinci Surgical System |
| United Therapeutics Corporation | $375.63 | 2024-2025 | Remodulin, Tyvaso, Orenitram |
| Astrazeneca Pharmaceuticals LP | $323.05 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $293.29 | 2023-2024 | |
| Insmed, INC. | $239.97 | 2024-2025 | Brinsupri, Arikayce |
| Actelion Pharmaceuticals US, INC. | $222.71 | 2024-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $130.81 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $128.78 | 2024-2025 | Winrevair |
| Philips North America LLC | $74.35 | 2024 | (Ak6) Vest Therapy |
| Pulmonx Corporation | $64.36 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Baxter Healthcare | $51.39 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $50.43 | 2024-2025 | |
| Grifols USA, LLC | $49.73 | 2024-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $48.61 | 2025 | Ohtuvayre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.38 | 2025 | Ofev |
| Abiomed | $33.34 | 2024 | Impella |
| Pfizer INC. | $30.24 | 2023-2024 | |
| Leo Pharma INC. | $26.66 | 2025 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $22.97 | 2024 | Glassia |
| Vifor Pharma, INC. | $22.38 | 2024 | Zemaira |
| Amgen INC. | $21.57 | 2025 | Tezspire |
| Inogen, INC. | $20.23 | 2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Ani Pharmaceuticals, INC. | $19.95 | 2024 | Purified Cortrophin Gel |
| Chiesi USA, INC. | $18.27 | 2025 | Cleviprex |
| Inspire Medical Systems, INC. | $14.23 | 2025 | Inspire |
| Novo Nordisk INC | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Wulff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.